Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01725100
Title A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

Advanced Solid Tumor

Therapies

Trametinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.